Publicaciones 2021

• First line maintenance treatment in metastatic colorectal cancer (mCRC): quality and clinical benefit overview Marta Martín-Richard and MARIA TOBEÑAJ Clin Med. 2021 Jan 26;10(3):470. doi: 10.3390/jcm10030470.2021
  
• «Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer» Albert Tuca, Rosa Gallego, Ismael Ghanem, Mireia Gil-Raga and Jaime FeliuJ Clin Med. 2020 Dec 11;9(12):4015. doi: 10.3390/jcm91240152021
  
• «Metastatic colorectal cancer. First line therapy for unresectable disease» Jorge Aparicio, Francis Esposito, Sara Serrano, Esther Falco, Pilar Escudero, Ana Ruiz-Casado, Hermini Manzano and Ana Fernandez-MontesJ Clin Med. 2020 Nov 30;9(12):3889. doi: 10.3390/jcm9123889.2021 
• «Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors – 2020 Update» Gerhard Jung, Daniel Benítez-Ribas, Ariadna Sánchez and Francesc BalaguerJ Clin Med. 2020. PMID: 331426892021
  
• Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval? Rodriguez A, Esposito F, Oliveres H, Torres F, MaurelJ.J Clin Med. 2021 Feb 13;10(4):746.2021
• Clinical impact of pre-surgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD1402 Trial Joana Vidal, David Casadevall, Beatriz Bellosillo, Carles Pericay, Rocio Garcia-Carbonero, Ferran Losa, Laura Layos, Vicente Alonso, Jaume Capdevila, Javier Gallego-Plazas, Ruth Vera, Antonieta Salud, Marta MArtín Richard, Miguel Nogué, Elena Cillan, Joan Maurel, Iris Faull, Victoria Raymond, Carlos Fernández-Martos, and Clara Montagut. Clinical Cancer Research. March 2021. In press

Publicaciones 2020

• Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials Maria C Riesco-Martinez 1 2, Carlos Fernandez-Martos 3, Cristina Gravalos-Castro 1, Paula Espinosa-Olarte 1 2, Anna La Salvia 1 2, Luis Robles-Diaz 1, Andrea Modrego-Sanchez 1, Rocio Garcia-Carbonero 1 2 Cancers (Basel). 2020. Dec 5;12 (12):3655.
• Correlation of RECIST, computed tomography morphological response, and pathological regression in hepatic metastasis secondary to colorectal cancer: the AVAMET study.
  Authors: Ruth Vera *, María Luisa Gomez, Juan Ramon Ayuso, Joan Figueras, Pilar García-Alfonso, Virginia Martínez Marin, Adelaida Lacasta, Ana Ruiz, Maria José Safont, Jorge Aparicio, Juan Manuel Campos, Juan Carlos Cámara, Marta Martín-Richard, Clara Montagut, Carles Pericay, José María Vieitez, Esther Falco, Monica Jorge, Miguel Marin, Mercedes Salgado, Antonio ViudezCancers (Basel). 2020 Aug 12;12(8):E2259. doi: 10.3390/cancers12082259.
  
• Comprehensive characterization of the mutational landscape in localized anal squamous cell carcinoma Corresponding author: Dr Juan Angel Fresno Vara
  Listed co-author(s): Dr Lucia Trilla-Fuertes, Dr Ismael Ghanem, Dr Joan Maurel, Dr Laura G-Pastrian, Dr Marta Mendiola, Dr Cristina Barreno, Mrs Rocio Lopez-Vacas, Mr Guillermo Prado-Vazquez, Dr Elena López-Camacho, Miss Andrea Zapater-Moros, Dr Victoria Heredia, Dr. Miriam Cuatrecasas, Dr Pilar García Alfonso, Dr. Jaume Capdevila, Dr Carles Conill, Dr ROCIO GARCIA-CARBONERO, Dr Karen E Heath, Dr. Ricardo Ramos, Dr Carlos Llorens, Dr Angel Campos-Barros, Dr Angelo Gamez-Pozo, Dr. Jaime FeliuTransl Oncol. 2020 Jul;13(7):100778. doi: 10.1016/j.tranon.2020.100778. Epub 2020 May 15.
  
• Genetic Profile and Functional Proteomics of Anal Squamous Cell Carcinoma: Proposal for a Molecular Classification Trilla-Fuertes L, Ghanem I, Gámez-Pozo A, Maurel J, G-Pastrián L, Mendiola M, Peña C, López-Vacas R, Prado-Vázquez G, López-Camacho E, Zapater-Moros A, Heredia V, Cuatrecasas M, García-Alfonso P, Capdevila J, Conill C, García-Carbonero R, Ramos-Ruiz R, Fortes C, Llorens C, Nanni P, Fresno Vara JÁ, Feliu J.Mol Cell Proteomics.2020 . apr; 19(4):690-700.

Publicaciones 2019

• SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). García-Albéniz X, Alonso V Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M2 Maurel J
  Oncologist. 2019 Nov;24(11):e1115-e1122. doi: 10.1634/theoncologist.2018-0728. Epub 2019 Jun 24.  
• Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial Carlos Fernández-Martos 1, Carles Pericay 2, Ferran Losa 3, Rocio García-Carbonero 4, Laura Layos 5, Nuria Rodríguez-Salas 6, Marta Martin-Richard 7, Vicente Alonso-Orduña 8, Ruth Vera 9, Javier Gallego 10, Jaume Capdevila 11, Antonieta Salud 12, Miquel Nogué 13, Joan Maurel 14, Inmaculada Guash 15, Clara Montagut 16, Carlos Lopez 17, Ismael Macias 2, Rakesh K Jain 18, Xabier Garcia-Albeniz JAMA Oncol 2019 Aug 29;5(11):1566-1573z

• Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02). García-Albéniz X, Alonso V Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M2 Maurel J
  Oncologist. 2019 Jun 24. pii: theoncologist.2018-0728. doi: 10.1634/theoncologist.2018-0728.

Publicaciones 2018

• Co-expression of p-IGF-1R and MMP-7 modulates panitumumab and cetuximab efficacy in RAS wild-type metastatic colorectal cancer patients. Vicente Alonso, Pilar Escudero, Carlos Fernández-Martos, Antonieta Salud, Miguel Méndez, Javier Gallego, Jose R. Rodriguez , Marta Martín-Richard, Julen Fernández-Plana , Hermini Manzano, Jose Carlos Méndez, Montserrat Zanui, Esther Falcó, Mireia Gil-Raga, Federico Rojo, Miriam Cuatrecasas, Jaime Feliu, Xabier García-Albéniz, Joan Maurel.
  Neoplasia Volume 20, Issue 7, July 2018, Pages 678–686

Publicaciones 2017

• Co-expression of p-IGF-1R and MMP-7 modulates panitumumab and cetuximab efficacy in RAS wild-type metastatic colorectal cancer patients. Vicente Alonso, Pilar Escudero, Carlos Fernández-Martos, Antonieta Salud, Miguel Méndez, Javier Gallego, Jose R. Rodriguez , Marta Martín-Richard, Julen Fernández-Plana, Hermini Manzano, Jose Carlos Méndez, Montserrat Zanui, Esther Falcó, Mireia Gil-Raga, Federico Rojo, Miriam Cuatrecasas, Jaime Feliu, Xabier García-Albéniz, Joan Maurel.
  ESMO Open. 2017 Aug 3;2(3):e000187. doi: 10.1136/esmoopen-2017-000187. eCollection 2017
• Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso V, Escudero P, Fernández-Martos C, Feliu J, Méndez JC, Méndez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz X, Camps J, Maurel J.
  Br J Cancer. 2017 Dec 5;117(12):1777-1786. doi: 10.1038/bjc.2017.279. Epub 2017 Nov 9
• Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients. Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, Maibach R, Aranda E, Marais R, Stahel RA.
  ESMO Open. 2017 Aug 3;2(3):e000187. doi: 10.1136/esmoopen-2017-000187. eCollection 2017
• Clinical relevance of colorectal cancer molecular subtypes. Rodriguez-Salas N, Dominguez G, Barderas R, Mendiola M, García-Albéniz X, Maurel J, Batlle JF.
  Crit Rev Oncol Hematol. 2017 Jan;109:9-19. IF: 5.1
• MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for Primary Rectal Cancer: longterm results from the GEMCAD 0801 trial. Patel UB, Brown G, Machado I, Santos-Cores J, Pericay C, Ballesteros E, Salud A, Isabel-Gil M, Montagut C, Maurel J, Ramón-Ayuso J, Fernandez-Martos C.
  Ann Oncol. 2017 Feb 14. IF:9.2
• Predictive Serum biomarkers in metastatic colorectal cancer patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (GEMCAD 09-01). Pineda E, Salud A, Vila-Navarro E, Safont MJ, García-Girón C, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Ayuso JR, Ripollés T, Bouzas R, Gironella M, García-Albéniz X, Feliu J, Maurel J.
  Tumor Biol. 2017 (in press). IF: 2.9
• Optimal Sequencing of Neoadjuvant Therapies (NAT) in Rectal Cancer: Upfront Chemotherapy vs. Upfront Chemoradiation.C Fernandez-Martos, A. Garcia- Fadrique and R Glynne-Jones.
  Article DOI: 10.1007/s11888-017-0358-5 Current Colorectal Cancer Reports. 2017. in press
• SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer.García-Carbonero R, Vera R, Rivera F, Parlorio E, Pagés M, González-Flores E, Fernández-Martos C, Corral MÁ, Bouzas R, Matute F.
  Clin Transl Oncol. 2017 Feb;19(2):135-148.

Publicaciones 2016

• Recomendaciones para el diagnóstico, estadificación y tratamiento de las lesiones pre-malignas y el adenocarcinoma de páncreas. Conferencia de Consenso. Martin-Richard M, Ginès A, Ayuso JR, Sabater L, Fabregat J, Mendez R, Fernández-Esparrach G, Molero X, Vaquero E, Cuatrecasas M, Ferrández A, Maurel J y Comité Multidisciplinar para la actualización de las recomendaciones para el manejo de las lesiones pre-malignas y el adenocarcinoma de páncreas.
  Med Clin. 2016 (in press). 1.1
• SEOM Clinical Guideline of localized rectal cancer (2016). González-Flores E, Losa F, Pericay C, Polo E, Roselló S, Safont MJ, Vera R, Aparicio J, Cano MT, Fernández-Martos C.
  Clin Transl Oncol. 2016 Dec;18(12):1163-1171.
• Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J.
  Med Clin (Barc). 2016 Mar 10. pii: S0025-7753(16)00063-4.
• SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL.
  Clin Transl Oncol. 2016 Dec;18(12):1172-1178. IF: 2.1

Abstracts presentados en ASCO 2016

• Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS/BRAF (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03).

Abstracts presentados en ESMO 2016

• PULSE, a phase 2 study of mFOLFOX6-panitumumab with biomarker stratification as first-line chemotherapy, in patients with KRAS (exon 2) metastatic colorectal cancer. A GEMCAD 09-03 study.
• Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02. A study from Spanish Digestive Cancer Group (GEMCAD)